Creating a new vaccine to fight tuberculosis
Developing a Multivalent Subunit Particle Vaccine Against Tuberculosis
This study is testing a new vaccine for tuberculosis that uses a special delivery system to help your body recognize and fight the bacteria, and if it works well, it could help people like you who are at risk for TB.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11325904 on NIH RePORTER |
What this research studies
This research focuses on developing a novel vaccine to combat tuberculosis (TB) by utilizing a unique adjuvant system that helps present multiple antigens from the bacteria Mycobacterium tuberculosis. The approach involves mixing well-characterized proteins from the bacteria with a special liposome that facilitates the formation of stable vaccine particles. This method aims to enhance the immune response against TB by ensuring that the vaccine components are effectively delivered to the immune system. Patients may benefit from this innovative vaccine if it proves effective in clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for tuberculosis infection or those who have been exposed to the bacteria.
Not a fit: Patients who are not at risk for tuberculosis or those who have already been vaccinated with existing TB vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine against tuberculosis, potentially reducing the incidence and burden of the disease.
How similar studies have performed: Other research has shown promise in developing vaccines using similar adjuvant systems, indicating a potential for success with this novel approach.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Lovell, Jonathan F — State University of New York at Buffalo
- Study coordinator: Lovell, Jonathan F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.